Latigo Biotherapeutics
Latigo Biotherapeutics is a clinical-stage biotechnology company developing non-opioid pain medicines. Their lead program, LTG-001, is a Nav1.8 inhibitor in Phase 1 clinical trials for acute and chronic pain. The company utilizes human genetics and advanced technologies to identify and develop novel pain therapeutics.
Buy Funded Startups lists
Funding Round: Series A
Funding Amount: $135M
Date: 14-Feb-2024
Investors: Westlake Village BioPartners, 5AM Ventures, Foresite Capital, Corner Ventures
Markets: Biotechnology, Pharmaceuticals, Pain Management, Biotechnology Research
HQ: Thousand Oaks, California, United States
Founded: 2018
Website: https://www.latigobio.com/
LinkedIn: https://www.linkedin.com/company/latigobio/
Crunchbase: https://www.crunchbase.com/organization/latigo-biotherapeutics
Leave a Comment
Comments
No comments yet.